CK-136 is an investigational, selective, oral, small molecule cardiac troponin activator. In preclinical models, CK-136 increased myocardial contractility by binding to cardiac troponin through an allosteric mechanism that sensitizes the cardiac sarcomere to calcium, facilitating more actin-myosin cross bridge formation during each cardiac cycle thereby resulting in increased myocardial contractility. Similar to cardiac myosin activation, preclinical research has shown that cardiac troponin activation does not change the calcium transient of cardiac myocytes.

CK-136 is the subject of a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose clinical study assessing the safety, tolerability and pharmacokinetics of CK-136 when administered orally as single or multiple doses to healthy participants.

CK-136 is an investigational product and is not approved by any regulatory agency. Safety and effectiveness have not been established.

Discover our other drug candidates

Omecamtiv Mecarbil

Omecamtiv mecarbil is designed to directly target the contractile mechanism, or pumping function of the heart.

About Omecamtiv Mecarbil


Aficamten is an investigational cardiac myosin inhibitor for the potential treatment of patients with hypertrophic cardiomyopathy (HCM disease).

About Aficamten


Reldesemtiv is an investigational fast skeletal muscle troponin activator for the potential treatment of amyotrophic lateral sclerosis (ALS).

About Reldesemtiv

  1. Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324(5):488-504.
  2. American Heart Association. Types of heart failure. Available at: Accessed 12/16/2022.
  3. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032.